Abstract
Nowadays there is no treatment option except antioxidant support which decelerates the progression of dry-type age-related macular degeneration (ARMD) which is one of the most common reasons for legal blindness in elderly people. Promising outcomes have been obtained with stem cell treatment and gene therapy in dry-type ARMD in the recent studies which are done in the light of the advanced bioengineering developments. In addition, very rapid advances have been developing related to the retinal prosthesis implantation which is performed to regain their functional vision in end-stage ARMD patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
